To include your compound in the COVID-19 Resource Center, submit it here.

Revlimid lenalidomide regulatory update

FDA began a safety review of Celgene's Revlimid lenalidomide after preliminary data from clinical trials showed

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE